The Cooper Companies, Inc.

What does CooperCompanies own?
CooperCompanies owns two business segments. CooperVision manufactures and markets contact lenses under brands including Biofinity, MyDay, Clariti, Avaira, and MiSight 1 day, along with private label lenses. CooperSurgical provides fertility and women's health products including IVF media, culture oil, catheters, and the PARAGARD intrauterine device. The company sells products in over 130 countries.

Is CooperCompanies publicly traded?
Yes. The Cooper Companies, Inc. trades on the Nasdaq Global Select Market under the ticker symbol COO. The company files annual reports (Form 10-K) and quarterly reports (Form 10-Q) with the U.S. Securities and Exchange Commission. Its fiscal year ends on October 31. CooperCompanies is a component of the S&P 500 index.

Who founded CooperCompanies?
CooperCompanies was founded in 1958 as Cooper Laboratories by Parker Montgomery, a Harvard-educated attorney who built the company through acquisitions in the healthcare equipment and services industry. The company was originally called Martin H. Smith Co. before changing its name to Cooper Laboratories, Inc. in 1967. The current corporate structure was established in 1987.

What is CooperCompanies' revenue?
CooperCompanies reported fiscal 2025 revenue of $4,092.4 million, up 5 percent from $3,895.4 million in fiscal 2024. The fiscal year ended October 31, 2025. CooperVision contributed $2,743.8 million, and CooperSurgical contributed $1,348.6 million. The company provided fiscal 2026 revenue guidance of $4,299 to $4,338 million.

Where is CooperCompanies headquartered?
CooperCompanies is headquartered in San Ramon, California. The CooperVision division maintains its operational headquarters in Pleasanton, California. CooperVision also has offices in Victor and Fairport, New York. Manufacturing facilities are located in Puerto Rico, New York, Costa Rica, Hungary, and the United Kingdom.

What is MiSight 1 day?
MiSight 1 day is a daily disposable soft contact lens approved by the FDA in November 2019 as the first and only product to slow the progression of myopia in children aged 8 to 12 at the initiation of treatment. It has also received approval in China and Japan. MiSight is a key growth product for CooperVision and is manufactured at the Ponce, Puerto Rico facility.

Has CooperVision had any recalls?
Yes. CooperVision issued several voluntary Class II recalls in 2024 and 2025 affecting MyDay Toric, Biofinity XR Toric, Biofinity Toric Multifocal, and Sofmed Breathables lenses. Issues included incorrect cylinder power, leaking blister seals, and invalid sterilization cycles in specific lots. All were classified as Class II by the FDA, and no permanent injuries were reported.

CooperCompanies traces its origins to 1958, when Parker Montgomery founded Cooper Laboratories. Montgomery, a 30-year-old Harvard-educated attorney and son of a Boston attorney, practiced law on Wall Street before entering the healthcare equipment and services industry. His approach directed Cooper Laboratories onto a growth path built on acquisitions and corporate deal-making, though this strategy also led to problems that eventually resulted in Montgomery's ouster from the company he had started.

The company originally operated as Martin H. Smith Co. before changing its name to Cooper Laboratories, Inc. in 1967. Through the 1960s and 1970s, Cooper Laboratories expanded through acquisitions across healthcare equipment and services. In 1978, the company reorganized into five independent business units focused on specialized market segments: Cooper Laboratories, CooperVision, Cooper Dental, Cooper Medical Devices, and Cooper International.

CooperVision was incorporated in 1980 as the contact lens focused division. The company went public in 1983. In 1987, CooperVision, Inc. changed its name to The Cooper Companies, Inc. and organized into three groups: Cooper Technicon, CooperSurgical, and CooperVision. This restructuring established the corporate framework that persists today.

A notable early product from CooperVision was Permalens, introduced in 1979 as the first contact lens approved for 30-day continuous wear. This innovation helped establish CooperVision's reputation in specialty contact lens design and extended-wear technology.

Through the 1990s and 2000s, CooperCompanies refined its portfolio to focus on two core segments. The company divested non-core businesses and concentrated investment in CooperVision and CooperSurgical. CooperVision built strength in toric lenses for astigmatism and multifocal lenses for presbyopia, segments requiring complex optical designs. The Biofinity line, using proprietary Aquaform silicone hydrogel technology, became one of the company's most successful products.

CooperSurgical grew through acquisitions in the fertility and women's health space. The segment provides medical devices and products for in vitro fertilization, obstetrics, and gynecology. The PARAGARD intrauterine device is among CooperSurgical's well-known products.

A defining regulatory milestone came in November 2019, when CooperVision's MiSight 1 day contact lens became the first and only product approved by the U.S. Food and Drug Administration to slow the progression of myopia in children aged 8 to 12 at the initiation of treatment. MiSight subsequently received approval from China's National Medical Products Administration in August 2021 and from Japanese regulators, expanding its global reach and establishing CooperVision as a leader in the emerging myopia management category.

In June 2023, CooperVision announced a $500 million multi-year investment to expand operations in Puerto Rico. The plan includes enlarging production facilities in Juana Diaz and establishing a new global manufacturing site in Ponce, which will manufacture MiSight 1 day among other products. The Ponce facility represents approximately $100 million of the total investment and is expected to employ 400 people in its initial phase.

In fiscal 2025, CooperCompanies reported revenue of $4,092.4 million, up 5 percent year over year. CooperVision revenue grew 5 percent to $2,743.8 million, and CooperSurgical revenue grew 5 percent to $1,348.6 million. The company provided fiscal 2026 revenue guidance of $4,299 to $4,338 million.

CooperVision operates a plastic neutrality program in partnership with Plastic Bank, launched in 2021. The program funds the collection and recycling of ocean-bound plastic equivalent to the weight of plastic used in participating CooperVision soft contact lens products, including the lens, blister, and packaging. As of January 2024, CooperVision reported collecting approximately 5.3 million kilograms of plastic through this partnership. The program covers 27 countries across the Americas, Europe, and Asia-Pacific. CooperVision states it is the first contact lens manufacturer to provide a full range of plastic neutral soft contact lenses.

Several CooperVision manufacturing sites hold green building certifications. The Alajuela and Coyol, Costa Rica facilities are LEED Gold certified. The Juana Diaz, Puerto Rico site is LEED Gold certified. The Scottsville and West Henrietta, New York sites are LEED Silver certified. The Mount Park, United Kingdom facility holds a BREEAM certification. A Madrid, Spain office is LEED certified.

CooperCompanies has not announced a formal net-zero emissions target or science-based emissions reduction commitment validated by the Science Based Targets initiative as of August 2026. The company's sustainability reporting focuses on manufacturing efficiency, waste reduction, and the plastic neutrality program.

As a medical device manufacturer, CooperCompanies is subject to FDA quality system regulations in the United States, CE marking requirements in Europe, and equivalent regulations in other markets. The company's manufacturing facilities are subject to regular regulatory inspections. No major FDA Warning Letters have been issued to CooperCompanies manufacturing facilities as of August 2026, per publicly available FDA inspection records.

CooperVision's MiSight 1 day received FDA approval in November 2019 as the first soft contact lens to slow myopia progression in children aged 8 to 12. This regulatory milestone is documented in FDA clearance records and represents a category-defining approval in the myopia management field.

The Biofinity family was named the best overall contact lens family by ContactLens.com's 2026 best contact lenses guide, recognized for covering standard, toric, and multifocal prescriptions within a single silicone hydrogel platform. Biofinity Multifocal was named best multifocal contact lens by Vision Center's 2026 eye doctor survey.

CooperVision's manufacturing facilities in Costa Rica and Puerto Rico have received LEED Gold certification from the U.S. Green Building Council. These certifications recognize energy and environmental design standards in manufacturing operations.

CooperVision has issued several voluntary Class II recalls in 2024 and 2025, all managed through standard FDA recall procedures. In February 2025, the company recalled 33,990 MyDay Toric lenses (FDA recall Z-1455-2025) due to incorrect cylinder power in specific lots. In June 2025, Biofinity XR Toric (397 units) and Biofinity Toric Multifocal lenses were recalled due to incomplete or leaking blister seals. In August 2025, MyDay Toric (4,140 units), Sofmed Breathables (180 units), and Voyant 1-Day Premium Toric were recalled due to an invalid sterilization cycle. An August 2024 recall affected 607 Biofinity XR Toric lenses due to a misaligned axis.

All recalls were classified as Class II by the FDA, meaning the products could cause temporary adverse health consequences but were unlikely to cause permanent injury. No deaths or permanent injuries were reported. The recall volumes were small relative to CooperVision's total production, and each was limited to specific lot numbers.

No major FDA Warning Letters have been issued to CooperCompanies manufacturing facilities as of August 2026. The company's contact lens products are FDA-cleared Class II medical devices subject to ongoing post-market surveillance and quality system requirements.

The contact lens industry has faced antitrust scrutiny regarding minimum advertised price policies that restricted online retailers from selling lenses below manufacturer-set minimum prices. CooperVision, along with other major manufacturers, was subject to this scrutiny, though specific enforcement outcomes related to CooperVision have not been separately documented in recent years.